68 results about "Podocyte" patented technology

The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.

The invention belongs to the field of biological recognition, and discloses a cell detection method, device and apparatus for a glomerular pathological section image, and the method comprises the steps: obtaining a to-be-detected glomerular pathological section image; inputting the to-be-detected glomerular pathological section image into a preset neural network model for identification and detection, with the preset neural network model being obtained by training a neural network through a predetermined number of glomerular pathological section images for identifying and labeling mesangial cells, endothelial cells and podocytes; respectively outputting probability graphs of mesangial cells, endothelial cells and podocytes in the glomerular pathological section image to be detected from three output channels of a preset neural network model; and calculating the number of the mesangial cells, the endothelial cells and the podocytes in the glomerular pathological section image to be detected according to the probability graphs of the mesangial cells, the endothelial cells and the podocytes. The causes and conditions of the patient are determined according to the number of mesangial cells, endothelial cells and podocyte, and a treatment scheme is made accurately.

Compositions are directed to the treatment of kidney diseases in a cell-specific manner. Methods of treating kidney diseases comprise the use of the compositions. Assays for identification of further compounds are provided. Biomarkers for predisposition to kidney diseases and diagnosis are identified.

This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer.

The invention provides a novel purpose of a microRNA-30 family, and concretely to an application of the family used as a podocyte injury marker for patients with focal segmental glomerulosclerosis (FSGS). In addition, the invention further provides an application of the microRNA-30 family in preparation of medicaments for treating the podocyte injury. According to the invention, the microRNA-30 family facilitates diagnosis for the patients with the focal segmental glomerulosclerosis (FSGS) and the preparation of the medicaments for treating the podocyte injury, and thus has an extremely important significance for diagnosis and treatment of chronic kidney diseases.

The present invention describes a non-invasive method to isolate with high efficiency, purity and reproducibility the population of renal progenitors CD133+CD24+, from urine samples of patients suffering from various glomerular diseases. Said renal progenitors can then easily be induced to differentiate into podocytes. The isolation of renal progenitors with the method of the invention allows the use of said cells as a cellular model of a disease for the in vitro study of genetic excluding exfoliated epithelial cells and blood cells mutations due to the podocyte or for the study of renal toxicity induced by potentially nephrotoxic drugs on the tubules.

The invention relates to a cultivation method for a mouse with a kidney podocyte specific knockout lncRNA DLX6-os1 transgene. The method can effectively achieve the effect of studying the action mechanism of podocyte injuries in different kidney diseases; according to the technical scheme, multi-generation crossbreeding is performed on an FLOX-DLX6-os1 transgenic mouse constructed in the earlier stage and another transgenic mouse carrying a podocyte specific NPHS2-Cre gene through a genetic engineering technology, and the cultivation of the mouse with the kidney podocyte specific knockout lncRNA DLX6-os1 transgene is achieved. The cultivation method for the mouse with the kidney podocyte specific knockout lncRNA DLX6-os1 transgene provides a very good animal model for defining the role ofthe lncRNA DLX6-os1 in the podocyte injuries, effectively achieves the effect of studying the action mechanism of the podocyte injuries in the different kidney diseases, and is an innovation of the cultivation method of transgenic mice.

Methods of treating kidney disease and protecting podocytes from injury are provided. Methods of screening agents for the treatment of kidney disease are also provided. In addition, methods of identifying structural or functional defects in a patient's podocytes and methods of identifying kidney disease causing agents in a patient's biological sample are also provided.

The invention belongs to the technical field of biochemistry, and provides a preparation method of human renal podocytes. The human renal podocytes conforms to an expression result of a human renal podocyte marker; and meanwhile, the preparation method is good in repeatability and simple to operate, and the human renal podocytes with high yield, higher value-added rate and high purity can be obtained.

The present invention identifies that glomeruli express many neuron-specific and especially synapse-specific protein similarities. In particular, the present invention identifies Rab3A expression, including the expression of altered forms, as well as expression of other synapse-specific proteins including neurotransmitter receptors. The invention further identifies that modulation of the activity of these synapse-specific proteins results in modulation of podocytes.

There is provided a method for promoting dynamin ring formation and/or maintenance of dynamin rings in a cell, comprising treating the cell with an effective amount of a dynamin ring stabilizer, or a prodrug or pharmaceutically acceptable salt of the dynamin ring stabilizer. The maintenance or accumulation of dynamin ring formation has particular application in the prophylaxis or treatment of a kidney disease or condition characterized by proteinuria. A dynamin ring stabilizer can be any agent that interacts with dynamin to promote dynamin ring assembly and/or inhibit dynamin ring disassembly. There are also provided methods for prophylaxis or treatment of podocyte dysfunction and/or maintaining or inducing actin cytoskeleton formation in a cell utilizing dynamin ring stabilizers, and for screening a test agent for use as a dynamin ring stabilizer.

This document provides methods and materials involved in assessing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of urinary CNP (e.g., a urinary to plasma CNP ratio) to determine whether or not a mammal is developing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials for using the level of urinary CNP levels to identify patients having an increased likelihood of experiencing a poor outcome are provided.